Publications of Patrick COLLINS
Bookmark and Share    
Full Text
See detailA Comprehensive Update of the Atypical, Rare and Mimicking Presentations of Mycosis Fungoides
LEBAS, Eve ULiege; COLLINS, Patrick ULiege; SOMJA, Joan ULiege et al

in Dermatology and Therapy (2021)

Introduction: Mycosis fungoides (MF) is the most frequent subtype of primary cutaneous T cell lymphomas (pCTCL). The diagnosis may be particularly difficult in the early stages as well as in atypical and ... [more ▼]

Introduction: Mycosis fungoides (MF) is the most frequent subtype of primary cutaneous T cell lymphomas (pCTCL). The diagnosis may be particularly difficult in the early stages as well as in atypical and rare clinical presentations. Furthermore, MF may simulate a large variety of common dermatologic disorders and patterns, both histopathologically and clinically. Methods: A literature search was performed to provide a comprehensive update on the rare and atypical MF manifestations as well as the dermatoses and dermatological patterns that could be imitated by MF. Results: A total of 114 publications were found describing a series of different dermatoses and dermatological patterns mimicked by MF, as well as some particular localizations of MF lesions and dermatoses that occur in preexisting MF lesions. Conclusions: The number of dermatoses that can be imitated by MF is ever-increasing. Patients with common dermatologic conditions that prove to be treatment refractory should be biopsied without delay, and sequentially as necessary, to prevent delay in diagnosis and progression of disease. Clinicopathologic correlation is the best way of diagnosis. [less ▲]

Detailed reference viewed: 26 (4 ULiège)
Full Text
See detailA rare malignant skin infiltrate
Bailleux, Sophie ULiege; Cao, Sandrine; DEZFOULIAN, Bita ULiege et al

Conference (2021, October)

A 9-month-old boy presented with urticaria-like cutaneous lesions. They appeared, for the first time, at the age of 5 months. The first clinical diagnosis was a mast cell disorder or urticaria pigmentosa ... [more ▼]

A 9-month-old boy presented with urticaria-like cutaneous lesions. They appeared, for the first time, at the age of 5 months. The first clinical diagnosis was a mast cell disorder or urticaria pigmentosa although antihistamines were not efficacious. Previously, the child was treated for thrombocytopenic purpura. A complete work up and systemic evaluation revealed severe thrombopenia. The bone marrow biopsy revealed no dyspoiesis in any of the cell lines. The final diagnosis was severe thrombocytopenic purpura in the context of an influenza-like syndrome. The treatment included systemic corticosteroids, sirolimus, rituximab, intravenous immunoglobulins and romiplostim. This immunosuppressive treatment led to a complete resolution of the skin lesions although recurrence was observed at treatment withdrawal. The clinical examination evidenced brownish and erythematous granulomatous plaques of the back, shoulders, face and thighs. A skin biopsy revealed a lymphoblastic infiltrate with blast cells sparing the dermis. Immunohistochemistry revealed a positivity for CD45, PAX5n CD79a, CD43 and CD34. The morphology and immunohistochemical profile were in favor of a cutaneous localization of an acute B-type lymphoblastic leukemia versus a B-type lymphoblastic lymphoma. The systemic workup showed no immunophenotyping abnormalities in the bone marrow and no malignant cells in the central nervous system but a tumefaction of both testicles. The testicular biopsy revealed an infiltration by a blastoid population expressing CD45, CD19 and CD34 whereas the cytogenetic revealed the presence of a partial 19p deletion and a MLL-AF10 rearrangement in 62% of nuclei. The child was treated by chemotherapy following the diagnosis of aleukemic leukemia cutis CD19+CD10-CD34+ CD20- with a testicular involvement and showed a good response. Aleukemic leukemia cutis is defined as a cutaneous infiltration of leukemic cells in the absence of both blood and bone marrow involvement. It is still not clear whether the malignant cells originate from the skin or spread from the bone marrow. The immature blast cells in the dermis and hypodermis clinically present as unspecific papules, nodules and plaques. Although rare and poorly characterized, recognition of this disease is important for early treatment. The management remains controversial. A diagnostic workup should include a blood test, bone marrow studies, FISH and cytogenetics. The treatment is similar as that for acute leukemia consisting in an induction and consolidation chemotherapy. [less ▲]

Detailed reference viewed: 22 (1 ULiège)
See detailNecrobiosis lipoidica following breast reduction
Absil, Gilles ULiege; COLLINS, Patrick ULiege; EL HAYDERI, Lara ULiege et al

Conference (2021, September 29)

Detailed reference viewed: 28 (5 ULiège)
Full Text
See detailNecrobiosis Lipoidica following Breast Reduction
Absil, Gilles ULiege; COLLINS, Patrick ULiege; EL HAYDERI, Lara ULiege et al

in Plastic and Reconstructive Surgery, Global Open (2021)

Necrobiosis lipoidica (NL) is a rare granulomatous skin disorder of unknown physiopathology that is frequently associated with diabetes mellitus. The typical skin lesions of NL present as chronic ... [more ▼]

Necrobiosis lipoidica (NL) is a rare granulomatous skin disorder of unknown physiopathology that is frequently associated with diabetes mellitus. The typical skin lesions of NL present as chronic, bilateral, well-defined red to yellow-brown plaques with telangectasias, a violaceous border and a waxy atrophic center. The lower legs are the most often involved areas, but NL may exceptionally develop on scar tissue following surgery. The treatment is very challenging and notoriously difficult. We report a 60-year-old diabetic woman who developed NL all along the surgical scars following breast reduction, without presenting NL on the lower legs. NL should be considered among the rare but possible skin healing complications of surgery. [less ▲]

Detailed reference viewed: 28 (15 ULiège)
Full Text
See detailThe impact of COVID-19 on the new diagnoses of melanoma
GEDEAH, Christophe ULiege; DAMSIN, Thomas ULiege; Absil, Gilles ULiege et al

in European Journal of Dermatology (2021), 31(4), 565-567

Detailed reference viewed: 22 (0 ULiège)
Full Text
See detailComment je traite… le mycosis fongoïde : à propos du brentuximab védotine, une nouvelle arme thérapeutique
LEBAS, Eve ULiege; COLLINS, Patrick ULiege; BONNET, Christophe ULiege et al

in Revue Médicale de Liège (2021), 76(4), 224-231

Récemment, le brentuximab védotine (BV) (Adcetris®) a obtenu le remboursement en Belgique pour le traitement du lymphome cutané primitif de type mycosis fongoïde (MF), du lymphome anaplasique à larges ... [more ▼]

Récemment, le brentuximab védotine (BV) (Adcetris®) a obtenu le remboursement en Belgique pour le traitement du lymphome cutané primitif de type mycosis fongoïde (MF), du lymphome anaplasique à larges cellules et de la papulose lymphomatoïde de type A. Le BV est un anticorps monoclonal dirigé contre le CD30 exprimé par les cellules T tumorales. L’inhibition de cette voie de signalisation induit un processus d’apoptose et conduit à la mort cellulaire. Le BV est remboursé après l’échec d’un autre traitement systémique et lorsque le nombre de cellules T atypiques exprimant le CD30 en immunohistochimie excède 10 % de la population totale sur une biopsie cutanée. Le BV est administré par voie intraveineuse toutes les 3 semaines à la posologie de 1,8 mg/kg, avec un maximum de 16 cures. Les taux de réponse globale excèdent 75 %. Certains patients négatifs pour le CD30 ont également montré une réponse thérapeutique intéressante. Les principaux effets indésirables du BV sont la neutropénie et la neuropathie périphérique. Les cas de deux patients avec un MF de longue date et multi-résistant, ayant répondu favorablement au BV, sont présentés dans cet article. [less ▲]

Detailed reference viewed: 37 (6 ULiège)
Full Text
See detailDual‑specificity phosphatase 3 deletion promotes obesity, non‑alcoholic steatohepatitis and hepatocellular carcinoma
Jacques, Sophie ULiege; Arjomand, Arash ULiege; Perée, Hélène ULiege et al

in Scientific Reports (2021), 11

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic hepatic pathology in Western countries. It encompasses a spectrum of conditions ranging from simple steatosis to more severe and ... [more ▼]

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic hepatic pathology in Western countries. It encompasses a spectrum of conditions ranging from simple steatosis to more severe and progressive non-alcoholic steatohepatitis (NASH) that can lead to hepatocellular carcinoma (HCC). Obesity and related metabolic syndrome are important risk factors for the development of NAFLD, NASH and HCC. DUSP3 is a small dual-specificity protein phosphatase with a poorly known physiological function. We investigated its role in metabolic syndrome manifestations and in HCC using a mouse knockout (KO) model. While aging, DUSP3-KO mice became obese, exhibited insulin resistance, NAFLD and associated liver damage. These phenotypes were exacerbated under high fat diet (HFD). In addition, DEN administration combined to HFD led to rapid HCC development in DUSP3-KO compared to wild type (WT) mice. DUSP3-KO mice had more serum triglycerides, cholesterol, AST and ALT compared to control WT mice under both regular chow diet (CD) and HFD. The level of fasting insulin was higher compared to WT mice, though, fasting glucose as well as glucose tolerance were normal. At the molecular level, HFD led to decreased expression of DUSP3 in WT mice. DUSP3 deletion was associated with increased and consistent phosphorylation of the insulin receptor (IR) and with higher activation of the downstream signaling pathway. In conclusion, our results support a new role for DUSP3 in obesity, insulin resistance, NAFLD and liver damage. [less ▲]

Detailed reference viewed: 62 (22 ULiège)
Full Text
See detailCutaneous Breast Cancer Metastases Successfully Treated Using an Oxygen Flow Assisted Topical Administration of Methotrexate (OFAMTX)
Jouret, Gaëlle ULiege; GONNE, Elodie ULiege; QUATRESOOZ, Pascale ULiege et al

in Dermatology and Therapy (2020)

Cutaneous metastases of breast cancer remain a therapeutic challenge. Oxygen flow-assisted topical administration of methotrexate 5% (OFAMTX, 5% methotrexate in a carrier solution) has recently been ... [more ▼]

Cutaneous metastases of breast cancer remain a therapeutic challenge. Oxygen flow-assisted topical administration of methotrexate 5% (OFAMTX, 5% methotrexate in a carrier solution) has recently been proven to be an efficacious alternative treatment for extramammary Paget’s disease, which is considered to be an in situ mammary adenocarcinoma of the epidermis. [less ▲]

Detailed reference viewed: 61 (5 ULiège)
Full Text
See detailRisankizumab-Aggravated Crusted Scabies in a Patient with Down Syndrome
SENTERRE, Yseult ULiege; Jouret, Gaëlle ULiege; Collins, Patrick ULiege et al

in Dermatology and Therapy (2020), 10(4), 829-834

Risankizumab, an interleukin (IL)-23 antagonist, is a highly effective treatment for moderate to severe psoriasis. Crusted scabies (CS) is a rare and severe form of scabies, occurring mainly in ... [more ▼]

Risankizumab, an interleukin (IL)-23 antagonist, is a highly effective treatment for moderate to severe psoriasis. Crusted scabies (CS) is a rare and severe form of scabies, occurring mainly in immunosuppressed patients and/or neurologically or mentally ill patients. A young girl with Down syndrome was diagnosed with a hyperkeratotic form of psoriasis. As treatment with topical dermocorticosteroids, UVB-phototherapy and acitretin for 6 weeks did not improve the lesions, two injections of risankizumab were administered. Following these injections, the lesions became rapidly even more severely crusted, and new lesions appeared on the extremities and the face of the patient. There was histological evidence of a high charge of scabies, leading to a diagnosis of CS. The patient was hospitalized and successfully treated by local permethrine and systemic ivermectine. This case suggests that even though anti-IL23 antagonists display an excellent overall safety profile, a particular caution for infections should still be respected in patients with underlying risk factors. © 2020, The Author(s). [less ▲]

Detailed reference viewed: 26 (0 ULiège)
See detailHistoséminaire : SMD et LAM (évaluation du nombre de blastes sur BOM)
COLLINS, Patrick ULiege; CHARLOTTE, Frédéric

Conference (2018, May 31)

Detailed reference viewed: 29 (2 ULiège)
See detailHistoseminar : Acanthamoeba infection presenting as skin lesions
COLLINS, Patrick ULiege; LE PELLETIER DE GLATIGNY, François

Conference (2017, October 27)

Detailed reference viewed: 24 (2 ULiège)
Full Text
See detailChimiothérapie, immunodépression et cancers secondaires : rapport d'un cas clinique
COLLINS, Patrick ULiege; Vijgen, S.; DE PRIJCK, Bernard ULiege et al

in Revue Médicale de Liège (2013), 7-8

We report the case of a multi-metastatic mucinous adenocarcinoma of the colon discovered pre-mortem in a patient with a history of multiple myeloma. This case gives the opportunity to discuss the ... [more ▼]

We report the case of a multi-metastatic mucinous adenocarcinoma of the colon discovered pre-mortem in a patient with a history of multiple myeloma. This case gives the opportunity to discuss the prognostic value of histological typing of colorectal cancer and secondary neoplasms to chemotherapy and/or immunodepression. [less ▲]

Detailed reference viewed: 184 (15 ULiège)